CCND1 and hyperlipidemia: The results of network pharmacology and bioinformatics analysis in the current study showed that AM might alleviate acquired hyperlipidemia by downregulating the expression of AKT1 and CCND1 and upregulating the expression of VEGFA and ESR1.